This site is intended for healthcare professionals
Biosimilars in retinal disease Learning Zone

Welcome

Read time: 132 mins
Last updated:28th Jul 2022
Published:28th Jul 2022

Now biosimilars are available for treatment of patients with retinal disease, what does this mean for patients, ophthalmologists, retinal disease specialists and other healthcare professionals? In this Learning Zone:

  • Watch expert video clips to get the fast facts on biosimilars, brush up on the basics and explore how they fit into management of retinal disease
  • Listen to our Advances in Ophthalmology Podcast Series to gain expert insights into how biosimilars may help to address unmet needs in the management of retinal disease, and the clinical evidence behind regulatory approvals
  • Explore the biosimilar development and approval process across Europe and the US, and how it differs to that of reference biologics and generic medicines

In this Learning Zone, learn about key challenges in management of retinal disease including high treatment cost, and how early treatment can improve visual acuity outcomes.

In our Advances in Ophthalmology Podcast Series, listen to experts discuss the development and approval process for biosimilars, and key clinical evidence for the first anti-VEGF biosimilar approved in the US and Europe. Insights are also provided on whether anti-VEGF biosimilars can help address unmet needs in retinal disease, and their potential to facilitate earlier access to treatment.

Check out expert video clips for fast facts on which anti-VEGF biosimilars have been approved for retinal diseases, key evidence for their efficacy and safety from clinical trials, and how biosimilars can be integrated into clinical practice.

Meet the experts

The following experts were involved in the development of the fast fact videos throughout the Learning Zone, or featured in the podcast series.

Sharma Pic.pngDr Ashish Sharma

Dr Ashish Sharma is an ophthalmologist at Lotus Eye Hospital in Coimbatore, India. He has published 90 articles in peer-reviewed journals and book chapters, and is principal investigator on an EMA and FDA phase 3 clinical trial of newer anti-VEGFs. Dr Sharma is on the reviewing and editorial board of high impact ophthalmology journals. He has been awarded an International Ophthalmologist Education Award by American Academy of Ophthalmology Board of trustees and Ophthalmic Hero of India by All India Ophthalmic Society.

Disclosures: Dr Sharma has been a consultant and speaker for Intas, Lupin, Novartis and Bayer.

Nancy Pic.pngDr Nancy Holekamp

Nancy M. Holekamp, MD is Director of Retina Services at the Pepose Vision Institute in St. Louis, Missouri. She has been a principal investigator in more than 38 national clinical trials dealing with age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. She has published 80 peer-reviewed publications and 22 book chapters. She has received the Senior Honor Award and the Secretariat Award from the American Society of Retina Specialists, as well as the Senior Honor Award from the American Academy of Ophthalmology, and the Suzanne Veronneau-Troutman Award in 2018.

Disclosures: Dr Holekamp has been on the speaker’s bureau for Allergan, Apellis, Genentech, Regeneron and Spark. She has received consulting fees from Applied Genetics Technologies Corporation, Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint Pharmaceuticals, Gemini, Genentech, Gyroscope, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Thea Laboratoires and Stealth Biosciences​. Dr Holekamp has also disclosed contracted research for Genentech, Gemini, Gyroscope and Notal Vision​, and intellectual property/patent with Katalyst Surgical.

Dr Anat Loewenstein.pngDr Anat Loewenstein

Dr Anat Loewenstein is a Professor of Ophthalmology and Vice Dean of the Faculty of Medicine at Tel Aviv University. Dr Loewenstein was the leader behind the development of novel technology for early detection of macular degeneration, the development of automated technology for detection of retinal disease activity and the development of augmented virtual reality to replace the operating microscope as well as development of home optical coherence tomography (OCT).

Dr Loewenstein has published more than 450 papers in peer reviewed journals, and contributed multiple chapters to ophthalmology textbooks. She is Chairman of the Department of Ophthalmology at the Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University, President of the Israeli Ophthalmological Society, and General Secretary of the Euretina board.

Disclosures: Dr Loewenstein for AbbVie, Bayer, Beyeonics, Notal Vision, Novartis and Roche.

Welcome: